Xgeva is not a bisphosphonate. It belongs to a completely different drug class called RANK ligand (RANKL) inhibitors. While both Xgeva and bisphosphonates are used to protect bones, they work through distinct mechanisms, behave differently in your body, and have different implications when you stop taking them.
What Xgeva Actually Is
Xgeva is the brand name for denosumab, a fully human monoclonal antibody. That means it’s a lab-made protein designed to target one very specific molecule in your body: RANKL, a signaling protein that tells your body to build and activate osteoclasts (the cells responsible for breaking down bone). By intercepting that signal, Xgeva prevents osteoclasts from forming, maturing, and surviving. Fewer active osteoclasts means less bone destruction.
The FDA has approved Xgeva for three cancer-related uses: preventing fractures and other bone complications in patients with bone metastases from solid tumors or multiple myeloma, treating giant cell tumor of bone that can’t be safely removed with surgery, and treating dangerously high blood calcium levels in cancer patients who haven’t responded to bisphosphonate therapy.
How Bisphosphonates Work Differently
Bisphosphonates take an entirely different approach. Instead of blocking a signal before bone-destroying cells form, bisphosphonates physically bind to bone tissue and get absorbed into osteoclasts when those cells start breaking bone down. Once inside the cell, bisphosphonates either inactivate or kill the osteoclast directly. Think of it this way: Xgeva stops the soldiers from being recruited, while bisphosphonates let the soldiers arrive but poison them on contact.
This distinction matters most when treatment stops. Because bisphosphonates embed themselves in bone, their protective effects linger for months or even years after you stop taking them. Denosumab works only while it’s circulating in your blood. Once you stop Xgeva, bone breakdown can resume rapidly, and bone loss may actually accelerate beyond what it was before treatment started. This “rebound” effect can lead to fractures as early as 60 days after a missed dose, which is why stopping Xgeva requires a careful transition plan, often involving a switch to a bisphosphonate to maintain bone protection.
How They’re Given
Xgeva is a subcutaneous injection, meaning it goes just under the skin in the upper arm, thigh, or abdomen. The standard schedule for bone metastases is one injection every four weeks. For giant cell tumor of bone, the schedule is more intensive at the start: injections every four weeks, plus extra doses on days 8 and 15 of the first month.
The most commonly compared bisphosphonate in cancer care, zoledronic acid, is given intravenously, typically as an infusion every four weeks. Zoledronic acid also requires dose adjustments for patients with reduced kidney function, a consideration that doesn’t apply to Xgeva. This is one practical reason oncologists sometimes choose Xgeva over a bisphosphonate: it’s simpler for patients with kidney problems.
Side Effects They Share
Despite their different mechanisms, Xgeva and bisphosphonates share two notable side effects: low blood calcium (hypocalcemia) and osteonecrosis of the jaw, a rare condition where jaw bone tissue begins to die.
Hypocalcemia is relatively common with Xgeva. In one study of cancer patients receiving denosumab for bone metastases, 35% developed low calcium within 30 days of their injection. Most cases were mild to moderate, but about 3% of patients experienced severely low calcium levels that required urgent attention. Symptoms of low calcium can include tingling in the fingers, muscle cramps, and in serious cases, heart rhythm changes. Calcium and vitamin D supplementation is typically part of any Xgeva treatment plan for this reason.
Osteonecrosis of the jaw (ONJ) occurs with both drug classes, though the pattern differs over time. A large retrospective study in Taiwan found that the incidence of ONJ was 1.47 per 1,000 person-years with denosumab compared to 2.49 per 1,000 person-years with bisphosphonates. The rates looked similar during the first two years of treatment, but from the third year onward, the difference became statistically significant, with bisphosphonate users developing ONJ at a higher rate. The severity of ONJ, when it did occur, was comparable between the two groups.
Why the Confusion Exists
People often assume Xgeva is a bisphosphonate because both drugs are prescribed in overlapping situations: bone metastases, osteoporosis (under its other brand name, Prolia, at a lower dose), and conditions where bone is breaking down too fast. In clinical trials, Xgeva was tested head-to-head against zoledronic acid, which reinforced the association. Doctors sometimes describe them together as “bone-protective agents” or “antiresorptive therapies,” umbrella terms that blur the line between two fundamentally different drugs.
The distinction isn’t just academic. It affects how long you stay on treatment, what happens if you miss a dose, whether your kidney function matters, how the drug is administered, and what your exit strategy looks like when it’s time to stop. If you’re being prescribed Xgeva, understanding that it’s a biologic antibody rather than a bisphosphonate helps you make sense of the monitoring and precautions that come with it.